Standardized Serenoa repens extracts, particularly hexanic extracts like Permixon®, show modest efficacy in improving lower urinary tract symptoms (LUTS) and quality of life in men with benign prostatic hyperplasia (BPH).
Clinical benefits include improvements in International Prostate Symptom Score (IPSS), peak urinary flow rate, nocturia, and some inflammatory markers, with a favorable safety profile.
Evidence from rigorous randomized controlled trials (RCTs) shows varied results; some large trials do not confirm superiority over placebo, but meta-analyses suggest small to moderate effects.
Combination therapies involving Serenoa repens with selenium, lycopene, or alpha-blockers may enhance symptom control compared to monotherapy.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
